Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: trt 2 Clear all
Completed Not applicable Interventional

An Analysis of Medication Adherence Using Televideo and Telephonic Monitoring and Utilization of an Education Protocol

NCT06696521
View directory record Official record
Conditions
Adherence, Medication, Cancer
Interventions
Intervention A- Telephone, Intervention B- Televideo
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

NCT00076011
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

NCT00576732
View directory record Official record
Conditions
Autistic Disorder, Autism
Interventions
Placebo, Risperidone high dose, Risperidone low dose
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
5 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

NCT03335033
View directory record Official record
Conditions
Carotid Artery Plaque
Interventions
Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination
Combination Product · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Sep 19, 2026, 10:54 PM EDT
Active, not recruiting Phase 2 Interventional

Olaparib In Metastatic Breast Cancer

NCT03344965
View directory record Official record
Conditions
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions
Olaparib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

NCT00093496
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
gemcitabine hydrochloride, tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 1 Interventional

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

NCT00323323
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
CHOP, Alemtuzumab, Plasma Samples
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Results available

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

NCT05919888
View directory record Official record
Conditions
Surgery, Surgical Site Infection, Cutibacterium Acnes, Prosthetic-joint Infection
Interventions
Povidone-Iodine, SURGX Wound Gel
Drug · Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

NCT00471276
View directory record Official record
Conditions
Breast Neoplasms
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Bakersfield, California • Burbank, California • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

NCT01268150
View directory record Official record
Conditions
Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
Interventions
Eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 19, 2026, 10:54 PM EDT
Active, not recruiting Phase 2 Interventional

Pilot Window of Opportunity Trial (POET)

NCT06129604
View directory record Official record
Conditions
Colorectal Carcinoma (CRC), Endometrial Carcinoma (EC)
Interventions
TPST-1495
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 1 Interventional

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

NCT00085358
View directory record Official record
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
carboplatin, paclitaxel, docetaxel, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 19, 2026, 10:54 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Trem-1 and Ultraviolet Radiation-induced Immune Suppression

NCT05020496
View directory record Official record
Conditions
Skin Diseases
Interventions
Diphenylcyclopropenone (DPCP)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 19, 2026, 10:54 PM EDT
Completed No phase listed Observational

Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy

NCT02661750
View directory record Official record
Conditions
Preparation for Colonoscopy
Interventions
Bowel Preparation
Drug
Lead sponsor
Gastroenterology Services, Ltd.
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 19, 2026, 10:54 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 228 to Treat Solid Tumors

NCT02437916
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
Interventions
AMG 228
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
La Jolla, California • New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

NCT04936308
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
50
States / cities
Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

NCT03769168
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Boise, Idaho • Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Results available

Envarsus Neurotoxicity Burden in Liver Transplant Patients

NCT03823768
View directory record Official record
Conditions
Neurotoxicity, Liver Transplant; Complications
Interventions
Envarsus, Tacrolimus Immediate release
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

NCT02000440
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental
Interventions
Losmapimod
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Results available

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

NCT02677116
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Olaratumab, Doxorubicin, Vincristine, Irinotecan, Ifosfamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 17 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 19, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Interventions
Ramucirumab, Atezolizumab, Peripheral blood draw, Biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 19, 2026, 10:54 PM EDT
Recruiting Phase 2 Interventional

A Study of IBI363 in Subjects with Advanced Solid Malignancies

NCT06281678
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Interventions
IBI363
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 19, 2026, 10:54 PM EDT